EMMA/ALICE
EMMA screens uterine bacteria for fertility impact, while ALICE detects harmful bacteria affecting embryos.
What are EMMA and ALICE tests?
Endometrial health is one of the key factors which can impact reproductive health, in fact studies have shown that as high as 20% of fertility problems are potentially caused by issues with the endometrium.
EMMA and ALICE are screening tests that assess bacteria in the uterine cavity. It is usual for bacteria to be in the uterine cavity, however, studies show that the presence of bacteria that cause inflammation or illness may be associated with embryo implantation failure.
Why would I have bacteria in my womb?
It is normal to have bacteria throughout the body, including in the vagina and womb. The body contains good bacteria that do us no harm and protect us from harmful bacteria. Occasionally, the number and type of bacteria can change (after illness or antibiotic treatment, for example).
Although there may be no signs of infection, changes in the microbiome can change conditions such as the acidity inside the womb, and this can affect fertility. Sometimes very low-grade infections within the womb can cause inflammation that may affect an embryo's ability to implant.
Who can benefit from EMMA or ALICE testing?
EMMA may be beneficial for any patient struggling to conceive. The EMMA test is recommended for most people as it provides more detail (including all of the screening included in the ALICE test) than the ALICE test, which is only advised for patients trying to conceive naturally but who have suffered from recurrent pregnancy loss.
We recommend EMMA for patients including people who have had three or more implantation failures following the transfer of good quality embryos or who have had a failed treatment using embryos created with donated gametes or donated embryos.
How are the tests done?
We take a small amount of endometrial tissue which is then analysed to provide a complete profile of the bacteria present in the tissue.
Are there any risks?
An endometrial sampling can be associated with a small risk of bleeding and infection. There is also a very small chance of uterine perforation.
In some cases, there is a “No-diagnosis” result, which could be due to bacterial DNA levels below the detection limit of the technique, sample degradation or sample contamination during collection or shipment. If this should occur, it will be assessed whether a new biopsy will be required.
Understanding the effectiveness of EMMA and ALICE
EMMA and ALICE tests are classified as an ‘add-on’ to treatment. The independent regulator of fertility treatment, the Human Fertilisation and Embryology Authority (HFEA), has developed a ‘red-amber-green’ rating system to provide information about treatments that are offered on top of your routine fertility treatment – known as treatment add-ons. They consider that the only way to be confident that a treatment is effective enough to be used routinely is to carry out a randomised controlled trial (RCT). In an RCT, patients are assigned randomly to two groups: a treatment group, given the new treatment and a control group, given either a well-tried treatment or a placebo.
For more information on treatment add-ons, please refer to the HFEA website
You must have all the information you need before you decide on which, if any, 'add-on' diagnostic tests or treatments to use.
Other fertility treatments
You might also find helpful
Learn how fibroids can affect fertility, their symptoms, and the treatment options available in our expert guide at Care Fertility.
Read MoreOur guide explores how vaginismus impacts fertility and offers compassionate, expert advice to support your journey to parenthood.
Read MoreDaniella’s story raises awareness about ectopic pregnancies, sharing signs, symptoms, and her journey to rebuild hope.
Read More